Inventiva SA Publishes 2025 Annual Report
Inventiva SA has published its 2025 Annual Report, detailing business updates and developments since the start of the financial year. Key highlights include results from a proof-of-concept trial for lanifibranor with empagliflozin and the appointment of Andrew Obenshain as the new CEO, effective October 1, 2025. The report also covers the company's financial position and activities for the first half of 2025, as outlined in the half-yearly financial report released on September 29, 2025. The full report is accessible via a provided link.
Inventiva SA has released its Board of Directors’ report to shareholders, outlining business updates and developments since the beginning of the 2025 financial year. The report highlights key events, including the announcement of results from a proof-of-concept trial evaluating lanifibranor in combination with empagliflozin. It also notes a transition in company leadership, with Andrew Obenshain appointed as the new Chief Executive Officer effective October 1, 2025, succeeding Fréderic Cren. The report references the company’s financial position, activities, and results for the first half of 2025, as detailed in the half-yearly financial report published on September 29, 2025. The full report can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
